Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Sep 24, 2016; 6(3): 505-516
Published online Sep 24, 2016. doi: 10.5500/wjt.v6.i3.505
Published online Sep 24, 2016. doi: 10.5500/wjt.v6.i3.505
Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders
Julie Morscio, Department for Imaging and Pathology, Translational Cell and Tissue Research, 3000 Leuven, Belgium
Thomas Tousseyn, Department of Pathology, University Hospitals Leuven, 3000 Leuven, Belgium
Author contributions: Morscio J wrote the paper; Tousseyn T revised the paper.
Conflict-of-interest statement: No potential conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Thomas Tousseyn, MD, PhD, Department of Pathology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. thomas.tousseyn@uzleuven.be
Telephone: +32-16-336582 Fax: +32-16-336622
Received: April 23, 2016
Peer-review started: April 24, 2016
First decision: June 6, 2016
Revised: July 8, 2016
Accepted: August 17, 2016
Article in press: August 18, 2016
Published online: September 24, 2016
Peer-review started: April 24, 2016
First decision: June 6, 2016
Revised: July 8, 2016
Accepted: August 17, 2016
Article in press: August 18, 2016
Published online: September 24, 2016
Core Tip
Core tip: At the moment different post-transplant lymphoproliferative disorders (PTLD) are grouped in broad categories (early, polymorphic, monomorphic and Hodgkin-like PTLD) and the Epstein-Barr virus (EBV) status is not taken into account. However, increasing evidence demonstrates that different malignant PTLD and EBV+ and EBV- lesions are clinically and biologically distinct, stressing the need for subtype-specific management. We propose that in future studies patients should be stratified according to the histological lymphoma subtype and the EBV status to minimize bias and to simplify the establishment and analysis of clinical trials.